🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 17 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/02/2024 52,03 54,48 52,03 54,00 +1,87% 4,71% 886.300
01/02/2024 52,25 53,96 51,79 53,01 +2,08% 4,15% 969.700
31/01/2024 53,48 53,90 51,85 51,93 -2,57% 3,83% 1.260.400
30/01/2024 53,68 53,80 52,44 53,30 -1,25% 2,53% 1.234.800
29/01/2024 52,90 54,30 52,35 53,98 +2,07% 3,69% 1.074.300
26/01/2024 52,50 53,80 51,02 52,88 +0,69% 5,30% 1.250.400
25/01/2024 51,66 52,79 50,42 52,52 +2,84% 4,59% 1.921.900
24/01/2024 53,67 54,98 50,89 51,07 -2,69% 7,62% 2.586.900
23/01/2024 53,99 54,90 50,20 52,48 -4,36% 8,70% 4.109.500
22/01/2024 53,39 55,20 53,29 54,87 +3,37% 3,57% 1.943.900
19/01/2024 54,91 54,91 52,69 53,08 -3,54% 4,04% 1.736.800
18/01/2024 55,30 55,69 54,11 55,03 -0,43% 2,85% 1.183.400
17/01/2024 54,95 55,50 54,04 55,27 -0,05% 2,66% 1.331.900
16/01/2024 56,01 56,72 55,05 55,30 -1,67% 2,98% 1.331.500
12/01/2024 57,12 57,86 55,44 56,24 -1,07% 4,24% 1.611.500
11/01/2024 59,48 59,50 56,79 56,85 -4,12% 4,56% 2.074.200
10/01/2024 63,64 64,19 58,81 59,29 -5,99% 8,45% 1.898.100
09/01/2024 65,69 65,71 62,10 63,07 -3,42% 5,50% 1.577.600
08/01/2024 64,54 65,30 64,04 65,30 +1,26% 1,95% 862.500
05/01/2024 63,85 65,40 63,55 64,49 +0,25% 2,90% 1.009.500
04/01/2024 63,12 65,39 62,54 64,33 +2,50% 4,52% 1.242.400
03/01/2024 62,95 63,49 60,96 62,76 -0,54% 4,02% 935.100
02/01/2024 61,90 64,44 61,42 63,10 +1,77% 4,88% 962.400
29/12/2023 61,97 62,53 61,20 62,00 -0,46% 2,15% 745.700
28/12/2023 61,05 62,49 60,88 62,29 +1,26% 2,64% 736.600
27/12/2023 61,28 62,16 60,60 61,51 +0,57% 2,55% 1.035.900
26/12/2023 59,95 61,60 59,73 61,16 +2,63% 3,12% 952.300
22/12/2023 59,35 60,06 58,86 59,59 +0,40% 2,02% 1.130.000
21/12/2023 58,77 59,55 57,95 59,35 +1,96% 2,72% 1.718.500
20/12/2023 59,66 59,66 56,22 58,21 -2,81% 5,77% 3.555.000